Spanish medical diagnostics company STAT-Diagnostica has completed a $28.5m Series C financing to support the launch of its DiagCORE near patient testing system in Europe next year.

The DiagCORE is an integrated molecular and immunoassay diagnostics system designed to operate in near patient testing (NPT) environments for acute care settings.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It can cater to the NPT for low-test volumes or as a platform to cover medium requirements for small and large-sized hospitals.

"STAT-Diagnostica’s DiagCORE system can become the best-in-class platform for decentralised molecular testing, the most attractive growth area in molecular diagnostics today."

DiagCORE is said to facilitate faster test turnaround times from sample to results and is aligned to clinical laboratory improvement amendments (CLIA) guidelines.

The process can be conducted in one step and can be performed on a range of samples on a single platform including whole blood, swabs, bronchoalveolar lavage (BAL), stool, sputum and offer up to 48-multiplex capabilities via real-time polymerase chain reaction (PCR).

The time taken to produce results can be as short as 30 minutes but up to 80 minutes, depending on the assay type.

DiagCORE’s performance is expected to improve clinical decision making and enhance the delivery of better patient management and at the same time save costs incurred by the healthcare system.

New investor in the financing programme Gilde Healthcare partner Arthur Franken said: "STAT-Diagnostica’s DiagCORE system can become the best-in-class platform for decentralised molecular testing, the most attractive growth area in molecular diagnostics today."

STAT-Diagnostica will implement DiagCORE on a range of decentralized testing environments, including critical care and emergency medicine units within hospitals. The system will also be incorporated with CLIA-waivable features that will enable it to be used in clinics and physician offices.